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ABSTRACT
As part of an anti-cancer natural product drug discovery program, we recently 
identified eusynstyelamide B (EB), which displayed cytotoxicity against MDA-MB-231 
breast cancer cells (IC50 = 5 µM) and induced apoptosis. Here, we investigated 
the mechanism of action of EB in cancer cell lines of the prostate (LNCaP) and 
breast (MDA-MB-231). EB inhibited cell growth (IC50 = 5 µM) and induced a G2 cell 
cycle arrest, as shown by a significant increase in the G2/M cell population in the 
absence of elevated levels of the mitotic marker phospho-histone H3. In contrast to 
MDA-MB-231 cells, EB did not induce cell death in LNCaP cells when treated for up to  
10 days. Transcript profiling and Ingenuity Pathway Analysis suggested that 
EB activated DNA damage pathways in LNCaP cells. Consistent with this, CHK2 
phosphorylation was increased, p21CIP1/WAF1 was up-regulated and CDC2 expression 
strongly reduced by EB. Importantly, EB caused DNA double-strand breaks, yet did 
not directly interact with DNA. Analysis of topoisomerase II-mediated decatenation 
discovered that EB is a novel topoisomerase II poison.
INTRODUCTION
During an anti-cancer natural product drug discovery 
program [1, 2], we recently identified eusynstyelamide 
B (EB) from the Great Barrier Reef marine ascidian, 
Didemnum candidum. This complex and unique 
bis-indole alkaloid displayed cytotoxicity (IC50 = 5 μM) 
and induced apoptosis in MDA-MB-231 breast cancer 
cells [3]. Marine organisms such as sponges and ascidians 
have been a prolific source of cytotoxic compounds 
several of which have been shown to target topoisomerase 
enzymes. Marine natural products belonging to the 
makaluvamine, pyridoacridine and xestoquinone structure 
classes have all been shown to interact and perturb 
topoisomerases [4]. The discovery of novel cytotoxic 
compounds is very important for the development of anti-
cancer treatments [5]. New cytotoxic drugs have been 
recently approved (eribulin, trabectedin, ixabepilone) and 
many are being tested in the clinic against chemoresistant 
cancers and in drug combination therapies [5–8]. 
Topoisomerase poisons are among the most 
widely prescribed anti-cancer drugs in clinical use. 
These cytotoxic drugs (e.g. etoposide, doxorubicin, 
and mitoxantrone) are frontline therapies for a variety 
of cancers [9, 10]. Topoisomerases are essential 
nuclear enzymes that play a major role in DNA 
replication, transcription, recombination, chromosome 
condensation and segregation [9, 11–13]. There are two 
major topoisomerase families. Type I topoisomerases 
make transient cuts in the DNA, regulating over- and 
under-winding within the double helix which reduces 
the stress accumulated ahead of replication forks 
and transcription complexes. Type II topoisomerases 
make transient double-strand breaks in DNA and 
modulates under- and over-winding, knotting, and 
tangling. Topoisomerase II can be found in two forms, 
topoisomerase IIα and IIβ [9, 11–13]. These isoforms are 
differentially expressed in cells and have separate nuclear 
functions. Topoisomerase IIα is regulated through cell 
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cycle and its maximal level peaks at the G2/M boundary. 
Moreover, this isoform is found in rapidly proliferating 
tissues and can be found in replication forks and associated 
with chromosomes during mitosis [9, 11–13]. In contrast, 
the β isoform is present in most cell types independent 
of their proliferation status and it appears to be involved 
in the transcription of hormonally and developmentally 
regulated genes [14, 15].
Topoisomerase II-inhibiting drugs can affect 
different stages of the catalytic cycle and are categorized 
into two groups: catalytic inhibitors and poisons. 
Catalytic inhibitors prevent the formation of the 
cleavage complex through inhibition of TOPO II binding 
caused by its intercalation into DNA [9, 11– 13, 16]. 
The bisdioxopiperazines, ICRF- 187 and ICRF-193 and 
the quinoline aminopurine are examples of catalytic 
inhibitors that stabilize the closed clamp intermediate, 
which is formed by the enzyme around the DNA, 
and blocks ATP hydrolysis [17, 18]. In contrast, 
TOPO II poisons stabilize the cleavage complex 
[9, 11– 13, 19], and can be categorized as interfacial 
or covalent [20, 21]. The interfacial poisons etoposide, 
doxorubicin, mitoxantrone, and bioflavonoids such as 
genistein bind non-covalently to the cleavage complex, 
intercalate into the DNA at the cleaved scissle bond 
and prevent religation. Covalent poisons have protein 
reactive groups, such as quinones, isothiocyanates, and 
maleimides that form adducts with the enzyme. The 
stabilization of the DNA cleavage complex leads to the 
formations of permanent double strand breaks when, for 
example, replication forks and transcription complexes 
try to transverse the cleavage. This can cause genome 
instability and chromosome translocations, which is 
associated with the development of some specific forms 
of leukemia [10, 22]. Currently, no drugs specific to 
topoisomerase IIα or β are available for clinical use. 
Results suggest that cardiotoxicity resulting from the 
use of the topoisomerase II-targeted drugs doxorubicin 
is due to its interactions with the β isoform [23]. There 
is also evidence that this isoform is responsible for 
initiating some of the secondary malignancies associated 
with topoisomerase-targeted drugs [24]. Compounds 
such as, NK314, tricitrinol B and Dp44mT favor 
TOPO IIα and aim for producing less off-targeted effects 
[25–28]. At the moment, four TOPO II-targeted drugs 
are in clinical development: F14512, versaroxin, C-1311 
and XK469 [10].
Here, we report mechanism of action studies on 
eusynstyelamide B (EB), providing a basis for further 
development of this agent (or optimized analogs) as a 
potential human breast and prostate cancer therapeutic. 
Our data indicated that EB inhibited the proliferation of 
LNCaP and MDA-MB-231 cells in vitro by inducing a G2 
arrest. Importantly, EB was found to be a non-intercalating 
topoisomerase II poison that activates DNA damage 
response pathways.
RESULTS
EB arrested growth of LNCaP cells
We recently demonstrated during a screening 
campaign of an ascidian-derived extract library that 
EB inhibited growth (IC50 5.0 µM) and caused cell 
death through apoptosis in MDA-MB-231 breast cancer 
cells [3]. As shown in Figure 1A, analysis of growth 
with a real-time cell analyzer (xCELLigence) revealed 
that EB exhibited a similar inhibitory potency in the 
prostate cancer cell line LNCaP (IC50 5.0 µM). Real 
time analysis of cell confluence by live cell imaging 
(IncuCyte FLR) demonstrated that 2.5 µM and 5.0 µM 
EB efficiently blocked growth of LNCaP cells up to 
96 h (Figure 1B). Yet, no typical morphological signs 
of cell death (cell shrinkage and membrane blebbing) 
were observed after 96 h (Figure 1C) or 10 days of 
treatment (Figure S1), suggesting that EB is cytostatic 
in LNCaP cells (36 h doubling time). Indeed, Western 
blot analysis of LC3B-II, a marker of autophagy, and 
cleaved PARP, a marker of late apoptosis, as well 
as Annexin V staining, a marker of early apoptosis 
(data not shown), confirmed that EB did not induce 
autophagy or apoptosis in LNCaP cells (Figure 1D). 
Notably, growth of the highly proliferative primary 
human neonatal foreskin fibroblast cell line NFF 
(IC50 1.3 µM, 24 h doubling time) and non-malignant 
prostate cell line RWPE-1 (IC50 0.92 µM, 22 h doubling 
time) was also inhibited by EB (Figure S2), suggesting 
that EB displayed higher potency in fast proliferating 
cell lines.
EB induced a G2 cell cycle arrest
Previous work by our group described a significant 
G2/M arrest of MDA-MB-231 breast cancer cells after 
treatment with 5.0 µM EB for 72 h [3]. A time course 
study of MDA-MB-231 and LNCaP cells revealed that EB 
induced a G2/M arrest in both cell lines as early as 24 h 
after treatment had commenced (Figure 2A). Concomitant 
with the increase of the G2/M cell population, EB largely 
reduced the G0/G1 cell population of MDA-MB-231 
cells with a modest decrease of the number of cells 
in S phase, while EB mainly affected the S phase cell 
population in LNCaP cells. Furthermore, the G2/M arrest of 
MDA-MB-23 cells was most pronounced after 48 h, after 
which the number of cells in G2/M visibly declined and 
the G0/G1 cell population increased, suggesting that the 
inhibitory effect of EB was in part temporary in the breast 
cancer cell line (Figure 2A). In contrast, the EB-induced 
G2/M arrest remained unchanged in LNCaP cells over 
the treatment period of 96 h (Figure 2A) and increased 
after 10 days of treatment (Figure S1). EB-treated MDA-
MB-231 cells consistently displayed higher levels of dead 
cells with hypodiploid DNA content (sub-G1) compared 
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to control when treated for 48 h or longer, while no such 
trend was visible in LNCaP cells (Figure 2A) even after 
10 days of treatment (Figure S1). A dose titration experiment 
(4.9 nM to 5 µM EB) for 72 h showed that concentrations 
of 0.625 µM EB and higher induced a visible increase of 
the G2/M cell population of MDA-MB-231 cells, while 
5 µM EB were required to visibly arrest LNCaP cells in 
G2/M (Figure 2B). Similar to the results above, there was a 
modest concentration-dependent increase in the number of 
dead cells (sub-G1) in the breast cancer cell line but not in 
LNCaP cells (Figure 2B). Treatment of LNCaP cells with 
5 µM EB for 72 h confirmed that EB significantly increased 
the number of cells in G2/M (p < 0.05) (Figure 2C).
With the purpose of determining if EB arrested 
LNCaP and MDA-MB-231 cells in G2 or in M phase of 
the cell cycle, two different experimental approaches were 
pursued. First, cell lysates of EB-treated cells were probed 
for the expression of the mitotic marker phospho-histone 
H3 (PHH3) by Western blotting. Elevated levels of PHH3 
indicate an increase in the amount of cells in mitosis 
[29]. This was observed with MDA-MB-231 and LNCaP 
cells when treated with taxol or nocodazole, which both 
arrest cells in mitosis (Figure 2D) [30, 31]. In contrast, 
EB treatment decreased the phosphorylation of histone 
H3 in MDA-MB-231 cells (Figure 2D), while PHH3 
levels remained unchanged in LNCaP cells (Figure 2D). 
The absence of increased PHH3 levels in both cell lines 
indicated that EB did not cause a mitotic arrest.
Next, the mitotic index of EB-treated MDA-
MB-231 and LNCaP cells was calculated by high content 
screening (HCS) based on PHH3 staining. EB treatment 
decreased the mitotic index in MDA-MB-231 cells by 
30-fold and in LNCaP cells by 3-fold (Figure 2E). Taken 
together, the increased G2/M cell population, absence of 
elevated PHH3 levels and reduced mitotic index after EB 
treatment together indicated that EB arrested LNCaP and 
MDA-MB-231 in G2 of the cell cycle.
EB treatment activates the DNA damage 
response pathway
To guide the characterization of the molecular 
mechanism underlying the EB-induced growth arrest of 
LNCaP cells, differential gene expression was studied 
by DNA microarray with a custom 180 k Agilent oligo 
microarray (VPCv3, ID032034, GPL16604). This prostate 
cancer focused array contains probes mapping to human 
protein-coding as well as non-coding loci; with probes 
targeting exons, 3’UTRs, 5’UTRs, intronic and intergenic 
regions [124]. With cut-offs of p ≤ 0.05 and fold change 
≥ 1.5, EB caused up-regulation of 2751 genes and 
down-regulation of 1743 genes (Figure 3). The 20 most 
differentially regulated genes after EB treatment of LNCaP 
cells relative to DMSO control are shown in Table S1.
Pathway analysis of differentially regulated genes 
with Ingenuity IPA software indicated that EB strongly 
changed the expression of 615 genes involved in cell cycle 
regulation and of 504 genes involved in DNA replication, 
recombination and repair. Many genes related to the role 
of BRCA1 in DNA damage response, such as CHEK2 and 
PLK1, were substantially down-regulated (17- and 48-fold, 
respectively). Pathways related to DNA repair, including 
homologous and non-homologous recombination, showed 
down-regulation of most of its genes. Furthermore, ATM 
signaling, which comprises part of the DNA damage 
response, was another pathway highly de-regulated by 
EB (Figure 3). EB treatment affected 28 out of 47 genes 
related to G2/M check point regulation and 44 genes out 
of 99 involved in p53 signaling, respectively. For example, 
EB treatment increased CDKN1A expression by 12-fold 
and MDM2 by 4-fold, and decreased BRCA1 expression 
by 17-fold and CHEK1 by 13-fold. 
Validation of microarray results by qRT-PCR 
and Western blotting analyses
Gene expression profiling by microarray analysis 
showed a strong differential regulation of genes involved 
in the control of cell growth, cell cycle and DNA 
damage response pathways. As shown by microarray 
analysis, the cell cycle regulation genes CDK1, CCNB1 
and CDC25A were transcriptionally down-regulated by 
14-, 12-, and 9-fold, respectively, while the CDK inhibitor 
CDKN1A which encodes the p21CIP1/WAF1 protein, was up-
regulated 12-fold. Similar levels of differential expression 
were observed by qRT-PCR (Figure 4A). Furthermore, 
expression of MKI67, which encodes the nuclear 
proliferation marker KI67, was suppressed 15-fold and 
25-fold as shown by the microarray and qRT-PCR analyses, 
respectively (Figure 4A). Consistent with the results of the 
microarray experiment, qRT-PCR demonstrated that the 
growth-arrest and DNA-damage-inducible stress response 
genes GADD45A and GADD45G were up-regulated by 
3-  and 2-fold, respectively (Figure 4A). In summary, 
qRT-PCR analysis of seven critical cell cycle regulatory 
genes confirmed the observation of the microarray study 
that EB-induced their differential expression in LNCaP 
cells. In MDA-MB-231 cells, EB treatment increased the 
expression of CDKN1A by 4-fold, while it decreased the 
expression of CCNB1 by 1.9- fold (Figure 4A). In addition, 
the transcription levels of CDK1, CDC25A, MKI67, 
GADD45A and GADD45G did not change substantially 
(fold change < 1.5) after EB treatment, suggesting cell line-
specific difference in the regulation of these genes.
In order to validate the gene profiling result and 
to further study the molecular basis of the EB induced 
G2 cell cycle arrest, the expression of proteins involved in 
DNA damage response and G2/M check point regulation 
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was investigated in both cell lines by Western blotting 
analysis. As controls, cells were treated with the DNA 
intercalator doxorubicin, which induces DNA damage 
by stalling topoisomerase II, the mitotic inhibitors taxol 
and nocodazole that target tubulin polymerization, and 
the autophagy inhibitor chloroquine [31–34]. The 
retinoblastoma tumor suppressor protein, RB, regulates 
cell proliferation by controlling G1-S phase progression of 
the cell cycle through its inactivation by phosphorylation 
[35, 36]. DNA damage can lead to RB dephosphorylation, 
Figure 1: EB arrested growth of LNCaP cells. (A) LNCaP cells were treated with the indicated concentrations of EB, and growth 
was monitored with a real-time cell analyzer (xCELLigence) for 72 h in three independent experiments. The IC50 was calculated by 
non-linear regression analysis of the dose response curves (n = 3, mean ± SD). (B) LNCaP cells were treated with 2.5 µM EB, 5.0 µM 
EB, 1.0 µg/mL tunicamycin (TUN, positive control), or vehicle control (DMSO). Cell growth as a function of increasing confluence was 
measured by real-time phase contrast imaging every two hours for 96 h on a live cell IncuCyte FLR system (n = 3, mean ± SD). (C) LNCaP 
cells were treated with 5.0 µM EB for the indicated times after which protein lysates were prepared and analyzed by Western blot analysis 
for the levels of PARP (116 kDa), cleaved PARP (89 kDa), LC3B-I (16 kDa), LC3B-II (14 kDa), and β-actin as a loading control. Control (C) 
cells were treated with the drug vehicle DMSO (0.1%) for 96 h. Other controls used were doxorubicin (Dox, 1 µM for 48 h), taxol 
(Tax, 2 nM for 24 h), and nocodazole (Noc, 83 nM for 24 h) as positive controls for PARP cleavage and chloroquine (Cq, 25 µM for 48 h) 
as a positive control for autophagy. Protein levels were quantified, normalized against the loading controls, and the results were expressed 
in relation to DMSO control (C). (D) Representative images of the analysis in B after 0 h and 72 h of treatment.
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Figure 2: EB induced a G2 cell cycle arrest. (A) Cell cycle distribution of LNCaP (left panel) and MDA-MB-231 cells (right panel) 
treated for the indicated times with 5 µM EB or 0.1% DMSO (control). DNA content was analyzed by flow cytometry, and the number of 
cells in the indicated cell cycle phases was quantitated. (B) LNCaP (left panel) and MDA-MB-231 cells (right panel) were treated for 72 h 
with the indicated concentrations of EB and analyzed as in A. (C) LNCaP cells were treated for 72 h with 5 µM EB or 0.1% DMSO (control) 
and analyzed as in A (n = 3, mean ± SD, *p < 0.05). (D) MDA-MB-231 (top panel) and LNCaP cells (bottom panel) were treated with 2.5 
µM and 5 µM EB, respectively, and extracted at the indicated time points for Western blot analysis with anti-phospho-histone H3 antibody 
(PHH3). β-actin levels were determined as loading control. As a control (C), cells were treated with the drug vehicle DMSO (0.1%) for 96 
h. Other controls used were the DNA damage inducer doxorubicin (Dox, 1 µM for 48 h), and the anti-mitotic drugs taxol (Tax, 2 nM for 
24 h) and nocodazole (Noc, 83 nM for 24 h). Protein levels were quantified, normalized against the loading controls, and the results were 
expressed in relation to the DMSO control (C). (E) Quantification of the mitotic index by HCS after phospho-histone H3 labelling. LNCaP 
and MDA-MB-231 cells were treated with 5 µM EB for 24 h and probed with anti-phospho-histone H3 antibody. Control cells were treated 
for 24 h with 0.1% DMSO or 83 nM of nocodazole. Quantification of PHH3 staining and calculation of the mitotic indices were carried out 
on the HCS instrument Operetta (PerkinElmer). Asterisks indicate results with p < 0.05 in a One-way ANOVA analysis.
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which causes a cell cycle arrest in G1 [37, 38]. In 
MDA- MB-231 breast cancer cells, EB treatment 
showed only moderate alterations in RB phosphorylation 
(Ser795, Ser807 and Ser811), indicating that G1-S phase 
progression was not affected by EB treatment (Figure 4B). 
On the other hand, the amount of phosphorylated RB 
at Ser807/811 reduced over time after treatment of 
LNCaP cells, while Ser795 phosphorylation remained 
unchanged (Figure 4B). It is unclear why these three 
CDK4/CYCLIN D target sites were differentially 
regulated in LNCaP cells. Nevertheless, loss in RB 
phosphorylation leads to RB activation and inhibition of 
S phase progression as indicated by the reduced number 
of cells in S phase (Figure 2). The mRNA levels of TP53, 
which encodes the p53 protein, did not change after EB 
treatment in LNCaP cells (data not shown). Protein p53 
is activated by phosphorylation in the presence of cellular 
stress, and regulates the expression and activation of 
molecules associated with cell cycle arrest, apoptosis, 
DNA repair, senescence, and metabolism. Increased 
phosphorylation of p53 was not detected up to 96 h after 
treatment of LNCaP cells with EB (Figure 4B). Instead, 
EB treatment temporarily reduced the expression of p53. 
In stark contrast to LNCaP cells, p53 phosphorylation and 
total p53 expression were substantially up-regulated in a 
time dependent manner in MDA-MB-231 cells (Figure 
4B). In the absence of cellular stress, p53 is expressed at 
low levels but upon stress stimuli like DNA damage is 
stabilized and activated by a series of post-translational 
modifications, such as phosphorylation by the kinases 
DNA-PK and ATM/ATR [39]. Like p53, CHK2 is also 
activated through phosphorylation by DNA-PK and ATM/
ATR following DNA damage [40]. EB treatment of both 
cell lines led to increased CHK2 phosphorylation. While 
CHK2 phosphorylation increased by approximately 
two-fold in a time-dependent manner in MDA-MB-231 
cells, it was strongly up-regulated (seven-fold) as early 
as 24 h post EB treatment in LNCaP cells (Figure 4B). 
Interestingly, the microarray results showed that CHEK2 
(CHK2) gene expression was down-regulated by 5-fold 
in EB-treated LNCaP cells; however, the expression of 
total CHK2 protein was not affected by EB treatment, 
as shown by Western blotting (Figure 4B). Activation of 
CHK1 kinase inactivates the phosphatase CDC25, which 
Figure 3: Microarray analysis of EB-treated LNCaP cells. (A) Venn diagram of differentially expressed genes of LNCaP cells 
treated with 5.0 μM EB for 24 h. (B) Ingenuity pathway analysis of G2/M DNA damage checkpoint regulation. EB caused up-regulation 
of 2751 genes and down-regulation of 1743 genes. The canonical pathway of G2/M DNA damage checkpoint regulation was overlaid with 
the microarray analysis-derived gene expression changes of LNCaP cells treated with 5.0 μM EB for 24 h. Genes in red were up-regulated 
and genes in green were down-regulated by the indicated values (fold change) relative to vehicle control (DMSO).
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removes the inhibitory Tyr15 phosphorylation of CDC2 
(CDK1) [41]. Increased phosphorylation of CHK1 was 
observed in breast cancer cells with a peak at 48 h post 
treatment (Figure 4B), whereas it was undetectable in 
LNCaP cells (data not shown). The CDC2/CYCLIN B 
complex is critical for the transition from G2 into mitosis. 
Entry of eukaryotic cells into mitosis is regulated by 
activation of CDC2 kinase through de-phosphorylation 
of CDC2 at Thr14 and Tyr15 [42–44]. EB treatment 
induced an accumulation of total CDC2 protein and 
inhibitory phosphorylation at Tyr15 in MDA-MB-231 cells 
(Figure 4B). When corrected for the up-regulation in 
total protein levels of CDC2, Tyr15 phosphorylation was 
increased by approximately 2-fold. The opposite was 
observed in EB-treated LNCaP cells (Figure 4B) where 
total CDC2 protein was markedly reduced at every time 
point. This is in agreement with the microarray and qRT-
PCR results which showed a 14- and 17-fold reduction in 
CDC2 gene expression after EB treatment of LNCaP cells 
for 24 h. While the inhibitory Tyr15 phosphorylation of 
CDC2 was slightly increased after 24 h of EB treatment 
when corrected for the decline in total CDC2 protein 
Figure 4: EB affected critical regulators of the G2/M DNA damage checkpoint and cell cycle. (A) LNCaP and 
MDA-MB-231 cells were treated for 24 h with 5 µM EB prior to RNA extraction and analysis of gene expression by qRT-PCR of the 
indicated genes. As a control, cells were treated with 0.1% DMSO for 24 h. Expression levels are shown as fold change relative to control 
(n = 3, mean ± SD, *p < 0.05, **p < 0.001, ***p < 0.0001). (B) LNCaP and MDA-MB-231 cells were treated with 5 µM and 2.5 µM EB, 
respectively, and extracted at the indicated time points for Western blot analysis with antibodies directed against the indicated proteins. 
β-ACTIN levels were determined as loading control. As a control (C), cells were treated with the drug vehicle DMSO (0.1%) for 96 h. 
Other controls used were the DNA damage inducer doxorubicin (Dox, 1 µM for 48 h), the anti-mitotic drugs taxol (Tax, 2 nM for 24 h) 
and nocodazole (Noc, 83 nM for 24 h), and the autophagy inhibitor chloroquine (Cq, 25 µM for 48 h). Protein levels were quantified, 
normalized against the loading controls, and the results were expressed relative to the DMSO control (C).
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levels, it was barely detectable at later time points, which 
was probably due to the strong loss of CDC2 protein. 
Consistent with the transcriptional changes of CDKN1A 
(p21CIP1/WAF1) (Figure 4A), expression of the kinase inhibitor 
was strongly induced in both cell lines after EB treatment 
(Figure 4B). The cyclin-dependent kinase inhibitor 
1 (p21CIP1/WAF1) works as a cell cycle regulator of G1 and 
S phase as well as an important mediator of cell cycle 
arrest at G2/M phase in response to DNA damage [45]. 
The expression of p21CIP1/WAF1 is up-regulated in the 
presence of low levels of DNA damage; however, at high 
levels of DNA damage, p21CIP1/WAF1 is proteolytically 
removed followed by induction of apoptosis [45]. Taken 
together, qRT-PCR and Western blot analysis corroborated 
above findings of the cell cycle and microarray analyses. 
Importantly, they demonstrated that critical regulators of 
the DNA damage pathways (GADD45, p53, CHK1, and 
CHK2) were activated.
EB caused DNA double strand breaks
The above studies demonstrated that MDA-MB-231 
and LNCaP cells reacted to EB treatment by differential 
regulation of genes and proteins involved in DNA damage 
pathways, suggesting that EB might induce DNA damage. 
In order to investigate whether EB causes DNA 
double strand breaks (DSBs), EB-treated LNCaP and 
MDA-MB-231 cells were analyzed by quantitative 
γH2AX foci and neutral COMET assays. DSBs 
induce phosphorylation of histone H2AX (γH2AX), 
generating foci in the nucleus that can be detected by 
specific antibodies [46]. In a time-dependent manner, 
EB substantially increased the number of γH2AX 
foci in LNCaP cells to levels seen after treatment with 
doxorubicin (Figure 5A). A strong increase in the number 
of γH2AX foci was also observed in MDA-MB-231 
cells when treated for 4 h with EB. Yet, longer treatment 
periods (72 h) generated visibly less DSBs, suggesting 
that part of the initial EB-induced DSBs was repaired 
(Figure 5A).
The analysis of DSBs by neutral COMET assay 
is based on the fact that DSBs result in the extension of 
DNA loops, which form a comet-like tail after neutral 
electrophoresis of lysed and salt-extracted nuclei [47]. The 
amount of DNA in the tail of the comets is correlated to 
the level of DNA damage [48]. While the tail length of the 
comets derived from LNCaP cells treated for 4 h with EB 
were comparable to the control, they were significantly 
increased after EB treatment for 72 h and similar to 
the doxorubicin control (Figure 5 B). The tail length of 
the comets of MDA-MB-231 cells was significantly 
increased after EB treatment for 4 h when compared to the 
control (Figure 5B). Yet, they were visibly shorter when 
MDA-MB-231 cells were treated with EB for longer 
periods of time (72 h), suggesting a reduction in the 
amount of DSBs over time and that part of the initial 
damage was repaired. In summary, EB induced DNA 
damage by causing DSBs in LNCaP and MDA-MB-231 
cells. Furthermore, both cell lines displayed distinct 
kinetics of EB-induced DNA damage, suggesting cell 
line-specific responsive mechanisms.
EB is a topoisomerase II poison
As shown above, EB treatment induced DSBs in 
LNCaP and MDA-MB-231 cells. In order to verify if the 
observed DNA damage was a result of a direct interaction 
of EB with DNA (e.g. DNA intercalation), two different 
techniques were used. In the first assay, the displacement 
of ethidium bromide (EtBr) intercalated in double-stranded 
DNA was measured. The fluorescence emitted by 
EtBr (excitation at 530 nm and emission at 600 nm) is 
around 30 times stronger when it is intercalated into 
DNA. Displacement by a competitor compound will 
therefore reduce the fluorescence intensity [49, 50]. 
The second assay measured changes to the melting 
temperature of double-stranded DNA. In both assays 
the fluorescent, DNA intercalating compound DAPI 
was used as a positive control. As shown in Figure 6A, 
DAPI displaced EtBr from the EtBr-DNA complex in a 
concentration-dependent manner, as indicated by 
the strong reduction in fluorescence (Figure 6A). 
In contrast, EB did not affect the fluorescence of the EtBr-
DNA complex even at the highest concentration tested 
(50 μM), which was almost 100-fold more than EtBr, 
suggesting that EB did not intercalate in DNA. Next, 
the thermal profile of double-stranded DNA complexed 
with fluorescent SYBR® Green was analyzed (Figure 6B). 
Melting curve analysis comprises the assessment of the 
dissociation characteristics of double-stranded DNA 
during heating. The melting point is the temperature 
at which 50% of the DNA is denatured and present as 
single-stranded DNA. The interaction of compounds with 
DNA can stabilize or destabilize its structure, affecting 
the melting temperature [51–53]. For example, DMSO is 
known to inhibit secondary structures of DNA and reduces 
the melting temperature of G/C-rich DNA sequences 
[54]. Consistent with this, DMSO shifted the melting 
temperature from 80.39°C to 78.34°C (Figure 6B).The 
dissociation of double-stranded DNA can be monitored 
using a DNA-intercalating fluorophore such as SYBR® 
Green, which fluoresces 1000-fold more intensely when 
intercalated [55]. Heat-induced denaturation of DNA leads 
to reduced binding of the fluorophore and can be measured 
by a reduction in fluorescence [56]. As shown in Figure 
6B, the positive control DAPI increased the DNA melting 
temperature by up to 10°C in a concentration-dependent 
manner (0.12 – 1.0 μM), indicating a physical interaction 
of DAPI with DNA which probably stabilized the double 
helix [57]. Consistent with this, DAPI displaced SYBR® 
Green from the DNA as indicated by a concentration-
dependent reduction of the median fluorescent 
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intensity of the DNA-SYBR® Green complex by up to 
2.8-fold. In contrast, EB did not affect the DNA melting 
temperature or caused displacement of SYBR® Green 
at all concentrations tested (6.25 – 100 μM, Figure 6B, 
Table S2). Taken together, both the displacement assay 
and DNA melting temperature analysis demonstrated that 
EB did not directly interact with DNA, suggesting that 
EB induced DNA double strand breaks were possibly 
mediated indirectly by targeting a DNA modifying 
enzyme.
Figure 5: EB caused DNA double strand breaks. (A) EB induced γH2AX foci formation. LNCaP and MDA-MB231cells were 
treated for 4 h and 72 h with 5 µM and 2.5 µM and EB, respectively. As controls, cells were treated with 0.1% DMSO for 72 h (control) 
or the DNA damage inducing agent doxorubicin (Dox, 5 µM) for 24 h. Fixed cells were reacted with antibodies directed against γH2AX 
(green), DNA was counterstained with DAPI (blue), and cells were visualized by immunofluorescence microscopy with a DeltaVision 
microscope (60 × objective). The number of foci per cell was quantified with Metamorph software (n < 100 cells, scale bar = 30 µm). (B) 
LNCaP and MDA-MB-231 cells were treated for 4 h and 72 h with 5 µM and EB, and DNA damage was analyzed by neutral single cell 
COMET assay. As controls, cells were treated with 0.1% DMSO for 72 h (control) or 5 µM doxorubicin (Dox) for 48 h. The amount of 
DSBs was quantified by measuring the length of the comet tails with CometScore software (n = 100 cells, *p < 0.05). Representative images 
of the comet tails are shown (bottom panels).
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Ascidians are a known source for compounds 
that induce DSBs via inhibition of topoisomerase II 
(topo II) [58]. TOPO II is an important enzyme that 
participates in DNA replication, transcription and 
chromosome condensation. It has the essential role of 
regulating the uncoiling of DNA through catalyzing 
transient breaks in the DNA duplex in an ATP-dependent 
reaction to release topological stress. An in vitro assay for 
TOPO II activity was carried out in order to determine 
whether EB caused DNA damage by inhibiting TOPO II 
[59]. EB was incubated with kinetoplast DNA (kDNA) 
and TOPO II, and the decatenation activity of TOPO 
II was analyzed by agarose gel electrophoresis (Figure 
6C). EB strongly decreased the decatenation of kDNA 
in a concentration-dependent manner, as judged by the 
decreased levels of decatenated DNA and increased levels 
of high molecular weight kDNA with low electrophoretic 
mobility (Figure 6C). Interestingly, 50 µM of EB were 
visibly more potent in inhibiting TOPO II than the 
equimolar concentration of the known TOPO II poison 
etoposide (Figure 6C). Next, the experiment was repeated 
in a modified format to test for the presence of linear DNA 
(covalently bound to TOPO II) which is a product of the 
cleavage reaction and indicative that EB acted as a TOPO II 
poison rather than a catalytic inhibitor. As shown in Figure 
6C, this analysis demonstrated that, with increasing 
inhibition of the decatenation reaction, EB generated 
linearized DNA in a concentration-dependent manner 
(Figure 6C), indicating that EB is a TOPO II poison.
DISCUSSION
We previously showed that EB displayed 
cytotoxicity against MDA-MB-231 cells through 
induction of apoptosis [3]. Here, we demonstrated that 
EB significantly arrested MDA-MB-231 and LNCaP cells 
in the G2 phase after 24 h in a time- and concentration-
dependent manner. G2 arrest is regulated by the DNA 
damage check point, which allows DNA repair by the 
different repair systems before entering into mitosis 
[60, 61]. The microarray results with LNCaP cells showed 
that EB activated pathways related to DNA damage 
and to G2/M check point regulation. EB-induced DNA 
damage was confirmed by observations of increased 
levels of γH2AX foci and a positive COMET assay after 
4 h treatment in LNCaP and MDA-MB-231. DSBs can 
have dangerous consequence for genomic stability and 
cell survival when not repaired. They may be partly 
recognized because of the destabilization of chromatin 
structure, which activates homologous recombination 
repair (HRR) or non-homologous end joining (NHEJ) as 
part of the DNA damage response [62–64]. The reduction 
in the number of DSBs in the breast cancer cell line after 
a longer incubation period suggests that the DNA was 
repaired. Nevertheless, this seemed not to have happened 
in the LNCaP prostate cancer cell line. Gene expression 
profiling indicated that BRCA1 and BRCA2, which are 
major players in the repair of DNA DSBs by homologous 
recombination, were down-regulated by 17- and 12-fold 
[65]. Genes involved in DSBs repair by NHEJ, such as 
PARP1, XRCC5, PRKDC, XRCC1 and DCLRE1C were 
also down-regulated [66]. These are the main DSBs 
repair systems in the cell, and their inactivation could 
be the reason for the accumulation of DSBs over time in 
EB-treated LNCaP cells. In many cases, chemoresistance 
of cancer cells to DNA damaging agents is because of 
increased DNA repair. Thus, co-targeting DNA repair 
mechanisms could cause hypersensitivity to DNA 
damage [67–69]. With this aim different compounds 
that target components of the DNA repair machine 
have been developed, such as O6-alkylating agents and 
temozolomide [70].
DNA damage is first detected by ATM, ATR and 
DNA-PK and can induce cell cycle arrest to allow DNA 
repair, or induce senescence or apoptosis. The arrest at 
G2/M phase prevents mitotic segregation of damaged 
chromatids and is mediated by ATM/ATR, CHK1 and 
p21CIP1/WAF1 [71–73]. Induction of the CDK inhibitor 
p21CIP1/WAF1 is required for nuclear sequestration of inactive 
cyclin B-Cdc2 complexes, leading to cell cycle arrest at 
G2. CHK1 activation through phosphorylation at Ser345 
and Ser317 is induced by ATR, after phosphorylation at 
Ser286 and Ser301 by CDKs for an efficient response to 
DNA damage [74]. Active CHK1 inactivates CDC25C by 
phosphorylation, impairing cell progression to mitosis, 
since it is responsible to activate CDC2 by removing 
the inhibitory phosphate groups Thr14/Tyr15 [75]. All 
cancer cells have a defect in G1 control and this makes 
them extremely dependent on S and G2/M checkpoints 
[76, 77]. Our microarray data showed that CHEK1 
(CHK1) was down-regulated by 13-fold and CDKN1A 
(p21CIP1/WAF1) was up-regulated by 12-fold in LNCaP cells 
treated with EB. The increase of CDKN1A was confirmed 
by qRT-PCR for LNCaP and MDA-MB-231 cells. 
Western blot results displayed that CHK1 was activated 
through phosphorylation at Ser345 after 24 h treatment of 
MDA-MB-231 cells with EB. The maximum amount of 
p-CHK1 was observed after 48 h treatment. Nevertheless, 
it has been reported that CHK1 is dispensable in the 
presence of a functional p21CIP1/WAF1 induction [77]. 
Transcription of TP53 and phosphorylation or 
stabilization of p53 protein was not observed in treated 
LNCaP cells but Ingenuity pathway analysis predicted 
TP53 as an activated upstream regulator with a z-score 
of 9.74 (data not shown). Moreover, TP53I3, which is 
directly regulated by TP53 was 48-fold up-regulated 
after treatment. In contrast, EB-treated MDA-MB-231 
cells increased phosphorylation and total p53 protein in a 
time dependent way. Phosphorylation of p53 at Ser15 is 
mediated by ATM and CHK2 in response to DNA damage 
[78]. Phosphorylation also occurs at Ser20 or Ser37 and 
promotes the stabilization and activation of p53. Protein 
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p53 is one of the inducers of the expression of p21CIP1/ WAF1 
and GADD45A, which were both up-regulated in 
LNCaP cells treated with EB as shown by microarray. 
Nevertheless, the data presented here suggested that 
the induction of p21CIP1/WAF1 and GADD45A in LNCaP 
cells was p53-independent. Cell cycle arrest induced by 
p21CIP1/WAF1 has been previously described by both p53-
dependent and independent pathways [79–81]. Apart 
from the tumor suppressor p53, p21CIP1/WAF1 can also be 
regulated by BRCA1 [82], CHK2 [83], and others.
Figure 6: EB inhibited topoisomerase II. (A) Fluorescent intercalator displacement assay. EB at the indicated concentrations was 
added to reactions containing plasmid DNA and EtBr, and fluorescence of EtBr was measured (λext = 210 nm, λem = 600 nm) in a FLUOstar 
Omega plate reader (n = 3, mean ± SD). DAPI at the indicated concentrations was used as a positive control for EtBr displacement. 
Asterisks indicate statistical significant results with p*** < 0.001 and p* < 0.05 in a One-way ANOVA analysis. (B) DNA melting 
temperature analysis. The temperature-dependent dissociation of SYBR® Green-stained double-stranded DNA in the presence of different 
concentrations of EB (6.25, 12.5, 25, 50 and 100 µM) was monitored on an Applied Biosystems 7900HT Fast Real-Time PCR instrument. 
DMSO and DAPI (0.12–1 µM) were used as controls. NCA, no compound added. The melting-curves shown are representatives of 
three replicates. (C) Topoisomerase II-mediated decatenation of kDNA in the presence of EB. The indicated concentrations of EB were 
incubated with topoisomerase II and kDNA, and reaction products were separated and visualized by agarose gel electrophoresis containing 
EtBr. Etoposide, a topoisomerase II poison, was used as positive control. 0.1% DMSO was used as vehicle control. In the second gel 
samples were reacted as described above, followed by proteinase K digestion, chloroform/isoamyl alcohol fractionation and agarose gel 
electrophoresis. The gel was stained with SYBR® Safe. Dec, decatenated kDNA; Linear, linear DNA; Cat, catenated kDNA. For better 
clarity, irrelevant lanes were removed from the image, as indicated by the gap.
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Despite the 5-fold down-regulation of CHEK2 
observed by microarray in LNCaP cells, an increased 
activation of CHK2 by phosphorylation at Thr68 
was noticed. The same was observed in EB-treated 
MDA-MB-231 cells. This activation is mediated by ATM 
and induces CHK2 dimerization [84]. After intermolecular 
phosphorylation, enzymatically active monomers 
leave chromatin to phosphorylate different substrates; 
including CDC25C that together with CHK1 leads to 
cell cycle arrest at G2/M phase [85, 86]. CHK2's role in 
G2/M arrest is not well defined. It is possible that CHK2 
activation is redundant in the presence of other checkpoint 
regulators [87]. CHK2 function could also be associated 
in controlling other proteins involved in the cell cycle, 
such as phosphorylating RB [88]. The CHK2 kinases 
inactivate CDC25 via phosphorylation at Ser216, blocking 
the activation of CDC2. The complex CDC2/CYCLIN B 
is of fundamental importance to the progress from G2 into 
mitosis. CDC2 is kept inactive during G2 phase through 
phosphorylation at Thr14/15 by WEE1 and MYT1 protein 
kinases [89–93]. The down-regulation of CDK1 (CDC2) 
gene expression (19-fold) in LNCaP cells was confirmed 
on the protein level by Western blot. After 24 h treatment 
the expression levels of CDC2 decreased dramatically, 
followed by loss of p-CDC2. In contrast, CDC2 protein 
accumulated in EB-treated MDA-MB-231 cells. However, 
this was accompanied by a greater increase in inhibitory 
CDC2 phosphorylation, suggesting that CDC2 activity 
overall was suppressed. Microarray and qRT-PCR showed 
that the expression of CCNB1 (CYCLIN B) was down-
regulated in MDA-MB-231 and LNCaP cells. Thus, the 
G2/M arrest after EB treatment of MDA-MB-231 cells 
was induced ultimately by inactivation of cdc2 and down-
regulation of CYCLIN B, along with CHK1 activation and 
p21 expression induced by p53 stabilization and activation. 
Another contribution for the G2/M arrest in LNCaP cells 
might have been GADD45A and GADD45G which were 
up-regulated after EB treatment and have been shown to 
inactivate CDC2/CYCLIN B kinase [94]. Thus, the results 
indicated that EB induced G2 arrest in LNCaP cells by 
down-regulation of CDC2 and CYCLIN B expression, 
which was maintained through up-regulation of GADD45 
and p21CIP1/WAF1. 
Studies have shown that overexpression of 
p21CIP1/WAF1 is related to induction of BAX and promotion 
of apoptosis [95, 96]. Consistent with this, EB induced 
apoptosis in the breast cancer cell line. Cell cycle 
distribution of treated MDA-MB-231 cells revealed 
an increase in the sub-G1 population, demonstrating 
that EB induced cell death. EB-induced apoptosis in 
MDA-MB-231 cells was confirmed by the detection of 
PARP cleavage. Nevertheless, high levels of p21CIP1/WAF1 
expression can also inhibit apoptosis through inhibition 
of PROCASPASE 3 activity [97], stabilization of the 
anti-apoptotic protein c-IAP1 [98], or down-regulation of 
caspase-2 [99]. These anti-apoptotic effects of p21CIP1/WAF1 
might explain why EB did not induce cell death in LNCaP 
cells when treated for up to 10 days. 
DSBs may be caused directly (replication/
transcription-independent) or indirectly (replication/
transcription-dependent) by cytotoxic compounds [68]. 
SSBs can become DSBs when a replication fork meets 
a SSB [100]. Similarly, collisions of RNA polymerase 
during transcription with TOPO II/DNA complexes 
can cause DSBs [101]. The induction of DSBs and 
activation of the DNA damage pathways by EB could 
have been due to a direct interaction of EB with DNA, 
such as binding or intercalation, induction of oxidative 
stress response or inhibition/poison of topoisomerases. 
EtBr displacement assay and DNA melting temperature 
analysis strongly suggested that EB did not directly 
interact with DNA. Instead, EB was found to inhibit 
TOPO II activity in vitro and to stabilize the cleavage 
complex. Microarray analysis showed that the expression 
of TOP2A was down-regulated by 49-fold, whereas 
transcription of the isoform TOP2B was only reduced 
by 1.3-fold. While TOP2A is cell cycle regulated by 
Rb and important for DNA synthesis and chromosome 
segregation; [102, 103]. TOP2B is mainly involved in 
transcription and has been shown to bind to the androgen 
receptor [104]. Thus, our findings indicate that EB is a 
topoisomerase II poison that, like etoposide, does not 
directly interact with DNA [105, 106].
It has been shown that BRCA1 is necessary for 
ubiquitination of topoisomerase IIα, which is correlated 
with higher DNA decatenation activity. Decatenation of 
chromatid arms happens before mitosis, while centromeric 
catenations persist till metaphase/ anaphase [107, 108]. 
Any problem during this process activates the decatenation 
G2 checkpoint signaling and can lead to G2 arrest in the 
absence of DNA damage [109, 110]. Our results indicate 
down-regulation of BRCA1, which could result in defective 
DNA decatenation [111]. Hence, DSBs and inhibition of 
chromatid decatenation caused by topo II poisoning might 
have caused the G2 arrest in EB-treated cells.
Besides its cytotoxicity towards LNCaP and MDA-
MB-231, EB showed to be cytotoxic to the non-malignant 
cell lines RWPE-1 and NFF. It is known that rapidly 
proliferating cells, such as RWPE-1 and NFF, are more 
sensitive to TOPO II inhibitors because they contain 
high concentrations of topoisomerase II, especially the 
α isoform [112–114]. Nevertheless, it has been reported 
that intrinsic characteristics of the cell line can also affect 
sensitivity to TOPO II catalytic inhibitors. For example, 
researchers have found that BRCA1 mutant cells are more 
sensitive to TOPO II catalytic inhibitors [18]. Moreover, 
defects in the G2/M checkpoint that regulates cell cycle 
by controlling the presence of catalytic TOPO II can also 
affect cell sensitivity [115–117].
Natural products are still the main source of 
topoisomerase II-targeting agents, and they usually 
contain polycyclic, aromatic, or planar structures 
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and intercalate DNA [28]. EB was shown to be a non-
intercalating topoisomerase II poison that arrests LNCaP 
and MDA-MB-231 cells at the G2 phase. Similar results 
were obtained with the treatment of MDA-MB-231 cells 
with the topoisomerase IIα inhibitor CS1. CS1 was less 
toxic than etoposide and showed potential  anti-multidrug 
resistance capabilities [118]. Further tests will determine 
EB toxicity and its preference for topoisomerase IIα or β 
isoform. Different strategies have been used to increase 
the potency and selectivity of topoisomerase II-targeting 
drugs. The development of compounds more specific 
to the α isoform can reduce adverse effects such as, 
cardiotoxicity and secondary malignancies. Another 
approach is the use of different drug delivery systems (e.g. 
polyethylene glycol and nanoparticles) to target tumors 
while sparing normal tissues or increase drug activity 
[119]. In order to increase the potency, drug combination 
approaches have revealed positive results. The use of 
PARP inhibitors are likely to be beneficial in specific 
tumors, such as in BRCA1-positive breast cancer cells 
[120]. Finally, combination treatment of doxorubicin with 
microRNA-21 inhibitor resulted in increased expression 
of tumor suppressor genes, increasing synergistically the 
anti-cancer activity of doxorubicin towards glioma in vitro 
[121].
In summary, our work shows that the natural product 
eusynstyelamide B (EB) is a novel topoisomerase II poison 
with comparable potency to the anti-cancer drug etoposide. 
Our findings warrant further studies investigating the 
efficacy of EB in various cancer models and potential 
synergies with clinically used anti-cancer drugs.
MATERIALS AND METHODS
Reagents
A stock solution of 10 mM EB was prepared 
in DMSO (Sigma-Aldrich) and sonicated to provide 
complete dissolution of the natural product. For cell 
treatment, the stock solution was diluted to the desired 
concentration in the appropriate complete cell culture 
medium. Tunicamycin, etoposide, chloroquine, taxol, 
and nocodazole were purchased from Sigma-Aldrich and 
dissolved in DMSO. Doxorubicin (Sigma-Aldrich) was 
dissolved in water.
Antibodies
The antibodies used in this study are described in 
Supplementary Table S3.
Cell culture
LNCaP and MDA-MB-231 cells were obtained 
from the American Type Cell Culture Collection. LNCaP 
cells were maintained in phenol-red free RPMI-1640 
medium (Life Technologies) supplemented with 5% 
fetal calf serum (FCS) (Life Technologies) at 37°C in an 
atmosphere containing 5% CO2. MDA-MB-231 cells were 
cultured in DMEM supplemented with 10% (v/v) FCS 
(Life Technologies).
Live cell analysis with xCELLigence and 
IncuCyte technologies
For real-time measurement of the cell index, 
which is a composite figure of cell number, morphology 
and adhesiveness, and computation of IC50, cells 
were analyzed on a xCELLigence system (Roche) as 
described previously.[122] LNCaP (1.0 × 104 cells per 
well), NFF (1.8 × 103 cells per well) and RWPE-1 cells 
(4.0 × 103 cells per well) cells were seeded in triplicate 
in 96-well E-plates® for 24 h. Cells were treated with 
the indicated concentrations of EB for 72 h, and the cell 
index measured hourly for 96 h. Calculations of IC50 
(72 h) from three independent experiments were 
performed with GraphPad Prism (GraphPad Software). 
For real-time live cell imaging, LNCaP cells were seeded 
in 96-well plates at 4.0 × 103 cells per well and grown 
to 20% confluence before addition of the indicated 
concentrations of EB or tunicamycin (1 µg/mL). Growth 
as a function of increasing confluence was monitored in 
real-time by phase contrast microscopy with the IncuCyte 
FLR system (Essen BioScience). Images were captured 
with a 10 × objective at 2 h intervals from 3 separate 
wells per treatment for 96 h, and mean ± SD of confluence 
percentages was computed.
Cell cycle analysis
LNCaP (2.0 × 105 cells per well) and MDA-MB-231 
(1.0 × 105 cells per well) cells were seeded in a 6-well 
plate for 24 h. For time course studies, cells were treated 
with 2.5 µM EB (MDA-MB-231) or 5.0 µM EB (LNCaP) 
for the indicated times. For the 10 day treatment with EB, 
LNCaP cells (2.5 × 104) were treated with 5 µM EB for 
72 h followed by periodic change of growth medium. For 
dose titration studies, LNCaP and MDA-MB-231cells 
were treated with the indicated concentrations of EB 
for 72 h. Cells were processed, and DNA content was 
analyzed by flow cytometry as described elsewhere [123]. 
The percentage of cells in each cell cycle phase was 
calculated with ModFit LT (Verity Software House) based 
on DNA histograms of 20,000 cells per treatment.
To calculate the mitotic index, LNCaP 
(1.0 × 104 cells per well) and MDA-MB-231 (5.0 × 103 
cells per well) cells were seeded in a 96-well plate for 
24 h. Cells were treated with 5 µM EB, 0.1% DMSO or 
83 nM nocodazole for 24 h. The cell culture medium was 
removed, and cells were fixed in 4% paraformaldehyde 
followed by incubation with blocking buffer (2% BSA 
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in PBS). Cells were then reacted with anti-phospho-
histone H3 (Ser10, 1:100, Abcam) overnight, and DNA 
counter stained with DAPI (1:500, Life Technologies) 
and Alexa Fluor® 568 donkey anti-rabbit IgG (1:500, Life 
Technologies). Samples were analyzed using the high-
content screening machine Operetta (PerkinElmer). The 
mitotic index was calculated with Harmony® software 
(PerkinElmer). Statistical significance (n = 3, mean ± 
SD) was analyzed with GraphPad Prism (GraphPad 
Software) by one-way ANOVA with Dunnett’s multiple 
comparison test.
Microarray gene expression profiling
For sample preparation, LNCaP cells were seeded at 
a density of 2.0 × 105 cells per well in a 6-well plate. After 
24 h, cells were treated with 5 µM EB or 0.1% DMSO 
for 24 h. Triplicates of each condition were prepared for 
microarray profiling as previously described [124].
The microarray raw data were processed using 
the Agilent Feature Extraction Software (v10.7) as 
described elsewhere [124]. Genes that were significantly 
different between two groups were identified with an 
adjusted p-value of ≤ 0.05, and an average fold change of 
≥ 1.5. The gene expression data have been submitted to 
Gene Expression Omnibus (GEO) with the accession 
number GSE74212. The filtered gene lists were examined 
by Ingenuity Pathway Analysis (IPA, Ingenuity Systems 
Inc.) for functional annotation and gene network analysis.
Quantitative real time polymerase chain reaction 
(qRT-PCR)
LNCaP (2.0 × 105) and MDA-MB-231 (1.0 × 105) 
cells were seeded in a 6-well plate for 24 h and treated 
with 5 µM EB or 0.1% DMSO for 24 h. Total RNA was 
obtained using the RNeasy mini kit (Qiagen) according 
to the manufacturer’s instructions. The quantity and the 
quality of the RNA were measured using a Nano-drop UV 
spectrophotometer (ThermoFisher Scientific). The samples 
were treated with DNAse I (Life Technologies), and cDNA 
was prepared from 2.0 µg total RNA with Superscript III 
(Life Technologies). Quantitative real-time PCR (qRT-
PCR) was performed with SYBR Green PCR Master 
Mix (Life Technologies) on a 7900HT Fast PCR System 
(Applied Biosystems). Data were analyzed with SDS2.3 
software (Applied Biosystems). mRNA expression levels 
were calculated by the ∆∆Ct method and normalized 
relative to the expression levels of the house keeping gene 
(RPL32) of the respective treatment and calculated relative 
to the vehicle control (DMSO). Statistical significance 
(n = 3, mean ± SD) was analyzed with GraphPad Prism 
(GraphPad Software) by Student's t test. The sequences of 
the primers used are listed in the Supporting Information 
(Table S4).
Western blotting
LNCaP (1.5 × 105 cells per well) and 
MDA-MB-231 (5.0 × 104 cells) were seeded in a 6-well 
plate and treated for the indicated times with 5.0 and 
2.5 µM EB, respectively. As positive controls, cells 
were treated with doxorubicin (1 µM, 48 h), etoposide 
(25 µM, 24 h), chloroquine (25 µM, 48 h), taxol 
(2 nM, 24 h), or nocodazole (83 nM, 24 h). 0.1% 
DMSO was used as vehicle control. At the end of the 
treatment, cells were harvested and lyzed with lysis 
buffer containing protease inhibitor cocktail (Roche) and 
phosphatase inhibitors [124, 125]. Protein concentration 
was determined through a bicinchoninic protein assay 
(BCA assay, Thermo Fisher Scientific). Thirty micrograms 
of protein lysates per well were loaded onto a NuPAGE® 
4–12% Bis-Tris Gel (Life Technologies) and transferred 
to a nitrocellulose membrane by wet transfer. After 
primary antibodies and secondary HRP conjugated 
secondary antibody incubation (Table S4), membranes 
were developed with a chemiluminescent HRP Substrate 
(Immobilon Merck Millipore). Beta-ACTIN was used 
as a loading control. Protein signals were quantified 
using Image Lab™ software (Bio-Rad), normalized to the 
respective loading control, and expressed relative to the 
control treatment. Phosphorylation levels were calculated 
relative to the normalized total amount of the respective 
protein.
DNA damage analysis
For quantitative analysis of γH2AX foci formation 
by fluorescence microscopy, LNCaP (6.0 × 104 cells per 
well) and MDA-MB-231 cells (3.0 × 104 cells per well) 
were seeded on glass coverslips (coated with poly-l-
ornithine for LNCaP) in a CO2 humidified incubator for 
24 h. Cells were treated with 0.1% DMSO, 5.0 µM EB, 
or 1.0 µM doxorubicin for the indicated times. Cells 
were fixed with 4% paraformaldehyde (Sigma-Aldrich) 
and stained as described previously with some minor 
modifications.[126] Cells were probed with anti-phospho-
histone H2AX (Ser139) antibody (1:500, Merck KGaA) 
at 4°C overnight, followed by Alexa Fluor® 488 goat 
anti-mouse IgG (1:500, Life Technologies) and DNA 
counterstaining with DAPI (1:500, Life Technologies). 
γH2AX foci were imaged with a DeltaVision microscope 
(GE Healthcare) and counted with MetaMorth software 
(Molecular Devices). A minimum of 100 cells were 
analyzed per sample.
For the analysis of DNA damage by neutral 
comet assay, LNCaP (2.0 × 105 cells per well) and 
MDA-MB-231 (1.0 × 105 cells per well) were seeded in 
a 6-well plate for 24 h. Cells were treated with 5.0 µM 
EB, 1.0 µM doxorubicin or 0.1% DMSO for the indicated 
times. The assay was performed as described previously 
with minor modifications [127]. Briefly, cells were 
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washed once with DPBS (Invitrogen) and harvested to 
obtain a single cell suspension of 1.0 × 106 cells/mL in 1x 
Tris-borate-EDTA (TBE, 89 mM Tris Base, 89 mM Boric 
acid, 2 mM EDTA). Approximately 4.0 × 103 cells were 
suspended into 150 μl of 0.6% low melting-point agarose 
(Sigma-Aldrich) and 60 μl of this mixture was applied onto 
each well of a COMET slide (Trivigen Inc). Slides were 
then placed on a cold surface (4°C) for 10 min followed by 
immersion in ice cold lysis buffer (2.5 M NaCl, 100 mM 
EDTA, 10 mM Tris, 1% Triton-X-100; pH 10) overnight. 
Slides were washed in 100 mL of 1 × TBE for 15 min at 
4°C. After removing excess salts with 1 × TBE, slides were 
placed in an electrophoresis tank (BioRad) containing 
1 × TBE buffer. Electrophoresis was performed for 
30 min at 70 V and 90 mA by adjusting the height of the 
buffer. After the completion of electrophoresis, slides were 
immersed in distilled water for 5 min followed by 5 min 
incubation in 70% ethanol. Slides were then incubated at 
45°C for about 10 min and left to cool down at RT. 100 μl 
of DAPI (1 μg/mL) we added onto each well and incubated 
at 4°C for 5 min. Excess DAPI was removed and slides 
were scanned using an epifluorescence microscope (Nikon 
Eclipse) equipped with a 10 × objective. One hundred 
comets in each sample were scored using the COMET 
Score software (TriTek Corp). Statistical significance 
(mean ± SD) was analyzed with GraphPad Prism 
(GraphPad Software) by one-way ANOVA with Dunnett’s 
multiple comparison test.
DNA interaction studies
An EtBr displacement assay was performed to 
identify the ability of EB to intercalate with DNA. 
As a positive control, increasing concentrations of the 
DNA intercalator DAPI (0.04–360 µM) were tested. 
Increasing concentrations of EB (6.25–50 µM) were 
incubated with 2.5 µg plasmid DNA in the presence of 
1.3 µM EtBr in a 96-well plate completed with TE buffer 
(10 mM Tris-Cl, pH 7.5 and 1 mM EDTA) to a final 
volume of 100 µl. Controls consisted of the individual 
reaction components (EtBr, DNA, and EB) and EtBr 
mixed with DNA. Each sample was set up in triplicate, 
and fluorescence was measured in a FLUOstar Omega 
plate reader (BMG Labtech) with an excitation at 530 nm 
and emission recorded at 605 nm. Readings were corrected 
for background fluorescence.
To study DNA binding of EB, increasing 
concentrations of EB (6.25 – 100 µM), DMSO (0.1%), 
or DAPI (0.12–1.00 µM) were added in triplicate to a 
completed qRT-PCR reaction run with SYBR® Green 
PCR Master Mix (Life Technologies) containing a 151 
bp PCR product of the RPL32 gene. Melting curves 
were generated with an Abi 7900HT qRT-PCR machine 
(Applied Biosystems) using the protocol: 50°C 2 min, 
95°C 15 s, 60°C 15 s, and 95°C 15 s with data recording 
of the temperature gradient between 60°C and 95°C. 
Thermal profiles were analyzed with SDS 2.4 software 
(Applied Biosystems).
Topoisomerase II assay
The topoisomerase II-mediated decatenation of 
kinetoplast DNA in the presence of EB (25-100 µM), 
etoposide (25-100 µM), or DMSO as vehicle control 
was carried out using the kDNA based Topoisomerase 
II Drug Screening kit (TopoGen) as described by the 
manufacturer. Samples were separated on a 1% (w/v) 
agarose gel by electrophoresis for 30 min at 100 V and 
visualized by EtBr staining under UV light with a Quantum 
ST4 (Vilber Lourmat) gel documentation system. To 
detect the linear DNA intermediate of the topoisomerase 
II reaction, samples were prepared and reacted as 
described above followed by proteinase K treatment 
(50 µg/mL, Sigma-Aldrich) for 15 min at 37°C. DNA 
was extracted by chloroform/isoamyl alcohol extraction 
(24:1, Sigma-Aldrich) before electrophoresis on a 1% (w/v) 
agarose gel containing SYBR® Safe (Life Technologies).
Appendix A. supplementary material
The following are supplementary material related to 
this article.
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